Cargando…

Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis

International policy for treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR TB) relies largely on individual patient data (IPD) from observational studies of patients treated under routine conditions. We prepared guidance on which data to collect and what measures could improve cons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campbell, Jonathon R., Falzon, Dennis, Mirzayev, Fuad, Jaramillo, Ernesto, Migliori, Giovanni Battista, Mitnick, Carole D., Ndjeka, Norbert, Menzies, Dick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2020
Materias:	Online Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045826/ https://www.ncbi.nlm.nih.gov/pubmed/31922953 http://dx.doi.org/10.3201/eid2603.190997

Ejemplares similares

Multidrug-resistant tuberculosis around the world: what progress has been made?
por: Falzon, Dennis, et al.
Publicado: (2015)

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2019)

A Systematic Review of Reported Cost for Smear and Culture Tests during Multidrug-Resistant Tuberculosis Treatment
por: Lu, Chunling, et al.
Publicado: (2013)

Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis
por: Fox, Gregory J., et al.
Publicado: (2016)

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
por: Masini, Tiziana, et al.
Publicado: (2022)

Numbers needed to treat to prevent tuberculosis
por: Matteelli, Alberto, et al.
Publicado: (2015)

Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method
por: Mitnick, Carole D., et al.
Publicado: (2016)

Global reporting on tuberculosis preventive treatment among contacts
por: Falzon, Dennis, et al.
Publicado: (2022)

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
por: Pontali, Emanuele, et al.
Publicado: (2019)

Tuberculosis control, and the where and why of artificial intelligence
por: Doshi, Riddhi, et al.
Publicado: (2017)

Practices of therapeutic drug monitoring in tuberculosis: an international survey
por: Margineanu, Ioana, et al.
Publicado: (2022)

Advances in clinical trial design for development of new TB treatments—Translating international tuberculosis treatment guidelines into national strategic plans: Experiences from Belarus, South Africa, and Vietnam
por: Brigden, Grania, et al.
Publicado: (2019)

Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis
por: Weyer, Karin, et al.
Publicado: (2018)

Effect of Duration and Intermittency of Rifampin on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis
por: Menzies, Dick, et al.
Publicado: (2009)

Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan
por: Trauer, James M., et al.
Publicado: (2016)

Rifampin-resistant/multidrug-resistant Tuberculosis in Alberta, Canada: Epidemiology and treatment outcomes in a low-incidence setting
por: Edwards, Brett D., et al.
Publicado: (2021)

Long-term Follow-up for Multidrug-resistant Tuberculosis
por: Shin, Sonya S., et al.
Publicado: (2006)

World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
por: Mirzayev, Fuad, et al.
Publicado: (2021)

Mycobacterium tuberculosis Beijing Genotype Resistance to Transient Rifampin Exposure
por: den Hertog, Alice L., et al.
Publicado: (2014)

The need to accelerate access to new drugs for multidrug-resistant tuberculosis
por: Cox, Helen S, et al.
Publicado: (2015)

Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru
por: Tierney, Dylan B., et al.
Publicado: (2016)

Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Sotgiu, Giovanni, et al.
Publicado: (2016)

The Role of Novel Approaches and New Findings in the Pharmacology of Tuberculosis Medicines in Improving Treatment Outcomes
por: Falzon, Dennis, et al.
Publicado: (2018)

Rifampin- and Multidrug-Resistant Tuberculosis in Russian Civilians and Prison Inmates: Dominance of the Beijing Strain Family
por: Drobniewski, Francis, et al.
Publicado: (2002)

Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

Pharmacovigilance and tuberculosis: applying the lessons of thioacetazone
por: Falzon, Dennis, et al.
Publicado: (2014)

Randomized Trials to Optimize Treatment of Multidrug-Resistant Tuberculosis: The time for action is now
por: Mitnick, Carole D, et al.
Publicado: (2007)

Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies
por: Hwang, Thomas J, et al.
Publicado: (2014)

Multidrug-resistant Tuberculosis Management in Resource-limited Settings
por: Nathanson, Eva, et al.
Publicado: (2006)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

Discordance in Mycobacterium tuberculosis Rifampin Susceptibility
por: Kalokhe, Ameeta S., et al.
Publicado: (2012)

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis
por: Furin, Jennifer, et al.
Publicado: (2016)

Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial
por: Milstein, Meredith, et al.
Publicado: (2016)

Pre-treatment loss to follow-up among children with multidrug-resistant tuberculosis in South Africa, 2008–2010
por: Moore, Brittany K., et al.
Publicado: (2020)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study
por: Ndjeka, Norbert, et al.
Publicado: (2022)

Multidrug-resistant tuberculosis in children: evidence from global surveillance
por: Zignol, Matteo, et al.
Publicado: (2013)

Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis
por: Campbell, Jonathon R, et al.
Publicado: (2020)

Tuberculosis preventive treatment in people living with HIV—Is the glass half empty or half full?
por: Oxlade, Olivia, et al.
Publicado: (2021)

Use of predicted vital status to improve survival analysis of multidrug-resistant tuberculosis cohorts
por: Brooks, Meredith B., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a1lnt9b4epv2j8ghsv5qgl3csj